Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from ANGLE plc ( (GB:CLBX) ).
CelLBxHealth has discontinued maintenance of its FDA establishment license and device listing for the Parsortix system, aligning its regulatory approach with how customers currently use the platform and reinforcing cost discipline. The company notes that more than 97% of Parsortix systems are used for in-house translational research and assay development, where an active FDA device listing offers no commercial benefit.
By cutting these regulatory maintenance costs, CelLBxHealth plans to reallocate resources toward revenue-generating activities, customer support and product development, while retaining the ability to reinstate the listing if future commercial opportunities warrant it. The company says the move will not affect its sales pipeline, market forecasts, customer partnerships or growth plans, and it continues to expand collaborations and lab-developed test programmes to strengthen its position in precision oncology.
The most recent analyst rating on (GB:CLBX) stock is a Hold with a £0.89 price target. To see the full list of analyst forecasts on ANGLE plc stock, see the GB:CLBX Stock Forecast page.
Spark’s Take on GB:CLBX Stock
According to Spark, TipRanks’ AI Analyst, GB:CLBX is a Neutral.
The overall stock score reflects significant financial challenges and bearish technical indicators, which are the most impactful factors. While recent corporate events and earnings call achievements provide some positive outlook, the financial and valuation concerns weigh heavily on the score.
To see Spark’s full report on GB:CLBX stock, click here.
More about ANGLE plc
CelLBxHealth plc is a circulating tumor cell intelligence company focused on innovative CTC solutions for research, drug development and clinical oncology. Its patent-protected Parsortix platform isolates CTCs from blood for downstream imaging, proteomic and genomic analysis, with revenues driven by product sales, laboratory services and lab-developed tests via CRO and clinical lab partnerships.
Average Trading Volume: 2,962,216
Technical Sentiment Signal: Strong Sell
Current Market Cap: £11.93M
For an in-depth examination of CLBX stock, go to TipRanks’ Overview page.